Farmaceutici, quali opportunità dopo l’exploit di Novo Nordisk

from Market Mover · host Il Sole 24 Ore

L’efficacia dimagrante della semaglutide, farmaco per il diabete, ha dato la spinta al titolo portandolo a diventare la prima società per capitalizzazione in Europa Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published Oct 14, 2023

Embed this episode

Attribution link and audio player

Ready to play

Farmaceutici, quali opportunità dopo l’exploit di Novo Nordisk

0:00 11:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Inflection Point Blockworks Inflection Point is a weekly podcast for institutional professionals navigating crypto’s transition from a retail-driven market to a core component of global finance. Hosted by Blockworks Research Analyst Marc Arjoon alongside Matt Hougan (CIO, Bitwise), David Lawant (Head of Research, Anchorage), and Michael Marcantonio (Head of DeFi, Galaxy), the show delivers top-down, institution-led analysis of ETF flows, policy, market structure, and macro. We cut through the noise to focus on the true inflection points shaping crypto’s institutional future.

Frequently Asked Questions

How long is this episode of Market Mover?

This episode is 11 minutes long.

When was this Market Mover episode published?

This episode was published on October 14, 2023.

Can I download this Market Mover episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!